SCHEMBL5541336

SCHEMBL5541336

CC(C)(C)OC(=O)c1ccc(NC(=O)N2CCC3(CC2)Cn2cc([N+](=O)[O-])nc2O3)cc1

nearest known ligand 0.39

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
KCNH2 Q12809 4/20 0.39
CYP2D6 P10635 1/20 0.37
HPGD P15428 1/20 0.37
EPHX2 P34913 2/20 0.37
RAB9A P51151 3/20 0.36
ALDH1A1 P00352 2/20 0.36
SMN1; SMN2 Q16637 2/20 0.36
GAA P10253 1/20 0.35
NPC1 O15118 2/20 0.35
MAPT P10636 2/20 0.35
KDM4E B2RXH2 1/20 0.35
MAPK1 P28482 1/20 0.35
TRPM8 Q7Z2W7 1/20 0.35
USP2 O75604 1/20 0.35
CYP3A4 P08684 1/20 0.35
PTGS1 P23219 1/20 0.34
SLC6A2 P23975 1/20 0.34
SLC6A4 P31645 1/20 0.34
KMT2A Q03164 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5543599 0.87 TRPM8 (0.39) KCNH2HPGDEPHX2ALDH1A1GAA
SCHEMBL5537221 0.84 TRPM8 (0.48) CYP2D6ALDH1A1GAATRPM8USP2
SCHEMBL5544407 0.84 GAA (0.47) KCNH2ALDH1A1SMN1; SMN2GAAMAPT
SCHEMBL5546724 0.82 KCNH2 (0.44) KCNH2ALDH1A1SMN1; SMN2MAPTUSP2
SCHEMBL5540194 0.79 KCNH2 (0.42) KCNH2ALDH1A1MAPTPTGS1SLC6A2
SCHEMBL5534763 0.78 KCNH2 (0.53) KCNH2RAB9AALDH1A1GAANPC1
SCHEMBL5546023 0.76 KCNH2 (0.41) KCNH2CYP2D6HPGDRAB9AALDH1A1
SCHEMBL5537871 0.75 KCNH2 (0.42) KCNH2ALDH1A1MAPTPTGS1SLC6A2
SCHEMBL14562842 0.75 KCNH2 (0.40) KCNH2ALDH1A1PTGS1SLC6A2SLC6A4
SCHEMBL5540019 0.75 CHRM2 (0.42) KCNH2ALDH1A1MAPTPTGS1SLC6A2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2570418-A2 2,3-dihydro-6-nitroimidazo[2,1-b]oxazoles compound OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2013-03-20 EP disclosed
EP-1555267-B1 2,3-DIHYDRO-6-NITROIMIDAZO[2,1-b]OXAZOLES OTSUKA PHARMA CO LTD (JP) 2013-01-16 EP disclosed
US-7262212-B2 2,3-dihydro-6-nitroimidazo[2,1-b]oxazoles OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2007-08-28 US disclosed
US-20060094767-A1 2,3-Dihydro-6-nitroimidazo[2,1-b]oxazoles OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2006-05-04 US disclosed
EP-1555267-A1 2,3-DIHYDRO-6-NITROIMIDAZO 2,1-b OXAZOLES OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2005-07-20 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060094767-A1 2,3-Dihydro-6-nitroimidazo[2,1-b]oxazoles NR2C2, NR4A3, NR4A2 KCNH2 3503/4885CYP2D6 728/4885HPGD 3159/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.